JW Theriac

JW’s vision in anti-cancer therapies is to change the paradigm of cancer treatment and improve the quality of life for cancer patients.
To this end, JW is focusing on the research and development of targeted anticancer and immune cell therapies.
Beginning with the first development of dendritic cell-based immune cell therapies in metastatic renal cell carcinoma, JW has increased its understanding of immuno-oncology through differentiated clinical development programs for a variety of carcinomas.
JW is also continuing to research biomarkers to predict which patients will benefit the most from anticancer and immune cell therapies.
In addition to the immuno-oncology portfolio, JW is investigating the signaling mechanisms involved in cancer development and developing a cancer treatment portfolio, specifically targeting Wnt and STAT signaling systems.

Cardiovascular disease includes any disease related to the heart or blood vessels.
JW is looking for a treatment that can improve cardiovascular management, focusing on hyperlipidemia and hypertension for patients who are threatened with life due to cardiovascular and metabolic diseases.
JW is also committed to ultimately improving quality of life and addressing unmet medical needs.
Livalo (component name pitavastatin) has been shown to be a safe treatment without the risk of diabetes, as it not only lowers the incidence of major cardiac events but also improves blood glucose control in s in Korean patients with acute infarction.
In addition, JW is developing various fixed-dose combination products using its technology to allow the patients with hyperlipidemia and hypertension to take the necessary drugs at once, and to increase the convenience of administration.

JW continues to develop its expertise in immunology and is striving to develop innovative medicines for patients with diseases such as atopy, gout, asthma and idiopathic pulmonary fibrosis.
JW's goal is to develop treatments that act on the molecular level to solve the root causes of chronic inflammatory diseases not managed by conventional symptom-relieving therapies.

Regenerative medicine is the field of medicine that replaces or regenerates human cells, tissues and organs to restore their original function.
JW's goal is to regenerate damaged areas by activating the body's own recovery mechanisms of previously unrecoverable tissues and organs.
JW is particularly interested in Wnt signals, which are involved in stem cell growth, differentiation and related signaling pathways, and is working on the development of therapeutics applicable to hair follicle regeneration, muscle and brain diseases, etc.

Rare disease is defined as a disease in which rare population is less than 20,000 or difficult to diagnose due to rare disease management law.
JW is working to develop effective therapies for patients with rare diseases including hemophilia.

Vision decline is a major health and social problem affecting more than one billion people around the world. Potentially limiting social interaction and independence, it affects patients' ability to work and leads to the development of depression and anxiety.
JW is currently working on the discovery of new therapies for the treatment of diseases such as age-related macular degeneration (AMD) and allergic conjunctivitis (AC) based on molecular-level mechanisms.